{"url_path":"/sec/ctso/8-k/2026-07-06/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/1175151/0001104659-26-080741-index.html","accession_number":"0001104659-26-080741","cik":"0001175151","ticker":"CTSO","issuer_name":"Cytosorbents Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1175151/0001104659-26-080741-index.html","primary_entity_key":"0001175151","primary_entity_name":"Cytosorbents Corp"},"word_count":382,"has_tables":true,"body_markdown":"**Item 3.01**\n**Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**\n\n \n\nOn June 29, 2026, CytoSorbents\nCorporation, a Delaware corporation (the “Company”), received a written notice (“Notice”) from the Listing Qualifications\nDepartment of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2)\nbecause the Company’s minimum Market Value of Listed Securities was below the minimum of $35 million required for continued listing\non the Nasdaq Capital Market (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided\nthe Company with 180 calendar days, or until December 28, 2026 (the “Compliance Date”), to regain compliance with the MVLS\nRequirement. If the Company regains compliance with the MVLS Requirement, Nasdaq will provide written confirmation to the Company and\nclose the matter.\n\n \n\nThe Notice does not result\nin the delisting of the Company’s common stock from the Nasdaq Capital Market. To regain compliance with the MVLS Requirement, the\nmarket value of the Company’s common stock must meet or exceed $35 million for a minimum of 10 consecutive business days during\nthe 180-day grace period ending on the Compliance Date, unless the Staff exercises its discretion to extend this ten consecutive business\nday period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The Company is evaluating potential actions to regain compliance with the MVLS\nRequirement and intends to actively monitor the market value of its listed securities. The Company may also, if appropriate, consider\nother options to regain compliance with Nasdaq’s continued listing standard such as by increasing its stockholders equity to at\nleast $2.5 million.\n\n \n\nIn the event the Company\ndoes not regain compliance prior to the Compliance Date, the Company will receive written notification that its securities are subject\nto delisting, at which point the Company may appeal the delisting determination. There can be no assurance that the Company will be successful\nin maintaining its listing of its common stock on the Nasdaq Capital Market.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: July 6, 2026\nCYTOSORBENTS CORPORATION\n\n \n \n \n\n \nBy:\n/s/ Dr. Phillip P. Chan\n\n \nName:\nDr. Phillip P. Chan\n\n \nTitle:\nChief Executive Officer"}